Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

Back to Search
Print
Bookmark Trial

NCT00788294

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Cypress, California, 90630, United States
See other locations
Contact
1-800-718-1021
ClinicalTrials.gov_Inquirie[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy Volunteers
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Generally healthy

- BMI of 18-30 kg/m2

- more than 50 kg bodyweight.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pregnant


- exposure to biologic type drugs within the last 3 months


- history of allergic or anaphylactic reaction to a biologic drug


- use of tobacco- or nicotine containing products that is more than what is in 5
cigarettes per day


- excessive alcohol use.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Healthy VolunteersPhase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
NCT02034565
  1. Neptune, New Jersey
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Healthy VolunteersPhase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
NCT02034578
  1. Baltimore, Maryland
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Healthy VolunteersEvaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers
NCT02207699
  1. Overland Park, Kansas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Healthy VolunteersAn Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects
NCT00879983
  1. Shanghai,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
Official Title  ICMJE Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study
Brief Summary The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Healthy Volunteers
Intervention  ICMJE
  • Biological: tanezumab
    Drug solution given intravenously only once at dose of 10 mg
  • Biological: tanezumab
    Drug solution given subcutaneously only once at dose of 5 mg.
  • Biological: tanezumab
    Drug solution given subcutaneously only once at dose of 10 mg.
  • Biological: tanezumab
    Drug solution given subcutaneously only once at dose of 19 mg.
Study Arms  ICMJE
  • Active Comparator: 10 mg IV
    Intervention: Biological: tanezumab
  • Active Comparator: 5 mg SC
    Intervention: Biological: tanezumab
  • Active Comparator: 10 mg SC
    Intervention: Biological: tanezumab
  • Active Comparator: 19 mg SC
    Intervention: Biological: tanezumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 14, 2009)		76
Original Estimated Enrollment  ICMJE
 (submitted: November 7, 2008)		72
Actual Study Completion Date  ICMJE June 2009
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Generally healthy
  • BMI of 18-30 kg/m2
  • more than 50 kg bodyweight.

Exclusion Criteria:

  • Pregnant
  • exposure to biologic type drugs within the last 3 months
  • history of allergic or anaphylactic reaction to a biologic drug
  • use of tobacco- or nicotine containing products that is more than what is in 5 cigarettes per day
  • excessive alcohol use.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00788294
Other Study ID Numbers  ICMJE A4091013
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP